Shatavari

Metadata

Approved Indications

Commission E (Germany)

• No Commission E monograph exists for Asparagus racemosus. The plant was not part of the European herbal tradition evaluated by Commission E in the 1980s-1990s.

ESCOP

• No ESCOP monograph exists. Asparagus racemosus is not within the scope of European Scientific Cooperative on Phytotherapy assessment, as the herb originates from the Indian subcontinent and does not have established European traditional use.

EMA/HMPC

• No EMA assessment report or community herbal monograph exists. The herb is not listed in the EU herbal substances inventory for medicinal use. It has neither been adopted nor rejected — it has simply never been evaluated by the HMPC.

Ayurvedic Pharmacopoeia of India

• Listed: Yes. Shatavari is an official drug in the Ayurvedic Pharmacopoeia of India (API).
• Traditional indications: Balya (strength-promoting), Vajikara (aphrodisiac), Stanyakara (galactagogue), Rasayana (rejuvenative tonic). Indicated for Raktapitta (bleeding disorders), Shukradosha (seminal disorders), Shotha (edema), Netra roga (eye diseases), Amlapitta (acid gastritis), and general debility.
• Classical text references: Shatavari is described in the Charaka Samhita under three important categories — Balya (strength and immunity promoting), Vayasthapana (anti-aging), and Madhura Skandha (sweet-tasting group). It also appears in the Sushruta Samhita and Ashtanga Hridaya as a Dhatri Rasayana (rejuvenating tonic for women).

Indian Pharmacopoeia

• Listed: Yes. Asparagus racemosus root is included in the Indian Pharmacopoeia with identity, purity, and assay specifications.

British Pharmacopoeia

• The therapeutic applications of Asparagus racemosus have been referenced in the British Pharmacopoeia, and the herb is recognized in traditional systems of medicine including Ayurveda, Unani, and Siddha.

United States

• Dietary supplement: Available as a dietary supplement under DSHEA (1994). Not listed as GRAS (Generally Recognized as Safe) by the FDA.

Agreement/Disagreement Between Regulatory Bodies

• No European regulatory engagement: Unlike herbs such as Black Cohosh or Vitex that have formal EU monographs, shatavari has never entered the European phytotherapy regulatory process. This reflects geographic origin rather than a negative assessment.
• Strong Ayurvedic endorsement: Within the Indian regulatory framework, shatavari is one of the most important and widely prescribed Rasayana herbs, with formal pharmacopoeia listing and thousands of years of documented use.
• Gap between traditional status and Western clinical validation: Shatavari’s position as a premier women’s health herb in Ayurveda is well established, but no Western regulatory body has evaluated or endorsed it. Recent RCTs (2022-2025) are beginning to narrow this gap, particularly for lactation and menopausal indications.

Conditions Treated

Primary — Lactation Support (Galactagogue)

• Evidence level: Fair (multiple small RCTs with positive signal)
• Shatavari is one of the most widely prescribed galactagogues in Ayurvedic practice. Multiple randomized controlled trials have evaluated its effect on breast milk production and prolactin levels.
• Gupta and Sharma (2011) demonstrated a three-fold increase in serum prolactin in the treatment group compared to controls (p < 0.05) in a double-blind RCT with 60 lactating mothers.
• A 2022 RCT (Shavari Bar study, published in Journal of Obstetrics and Gynaecology) demonstrated improved breast milk output in a double-blind, prospective, randomized controlled trial using a shatavari-based formulation.
• A 2025 RCT (published in Journal of Obstetrics and Gynaecology) enrolled postpartum women receiving 300 mg shatavari root extract daily for 72 hours postpartum. The shatavari group showed significantly shorter time to breast fullness, higher milk volume at 72 hours, and greater maternal satisfaction (52.6% vs. 25.0% in placebo). No adverse effects were observed.
• However, the LactMed database (NCBI) notes that results of clinical studies on the galactagogue activity of wild asparagus are mixed, and some studies evaluated shatavari as part of herbal mixtures rather than as a standalone agent.

Secondary — Menopausal and Perimenopausal Symptoms

• Evidence level: Emerging (recent RCTs with positive direction)
• A 2025 randomized, double-blind, placebo-controlled trial (published in Journal of the American Nutrition Association) recruited 75 early perimenopausal women aged 40-50. Both 50 mg and 100 mg daily doses of standardized Asparagus racemosus extract produced significant decreases in Menopausal Rating Scale scores (51.4% and 72.9% reduction vs. 22.8% for placebo). Hot Flash Weekly Weighted Scores decreased by 27.6% and 39.8% respectively vs. a 7.7% increase in the placebo group. Dose-dependent improvements were observed in FSH, LH, AMH, and 17-beta-estradiol levels.
• A separate 2025 eight-week, three-arm RCT (published in Frontiers in Reproductive Health) compared 300 mg shatavari root extract alone, a combination of 300 mg shatavari with 250 mg ashwagandha, and placebo for menopausal symptoms. Shatavari alone was effective, and the combination showed enhanced results.
• Another 2025 RCT (published in International Journal of Women’s Health) evaluated 200 mg/day of standardized shatavari extract (CL22205) over 120 days in 50 perimenopausal women, reporting significant improvements in climacteric symptoms including mood, anxiety, and brain fog.

Secondary — Menstrual Irregularity

• Evidence level: Preclinical and traditional only
• Ayurvedic practitioners prescribe shatavari for dysmenorrhea, amenorrhea, and menorrhagia. The phytoestrogenic activity of shatavarins and sarsasapogenin provides pharmacological plausibility for menstrual regulation.
• Shatavarin I has been shown to competitively block oxytocin-induced uterine contractions in rat, guinea pig, and rabbit uteri (both in vitro and in vivo), suggesting an antispasmodic mechanism relevant to dysmenorrhea.
• No controlled clinical trials have evaluated shatavari specifically for menstrual irregularity as a primary endpoint.

Traditional — Ayurvedic Indications

• Female reproductive tonic (Stri Rasayana): The primary traditional use. Shatavari is prescribed across all stages of female reproductive life — menarche, menstruation, fertility, pregnancy (in some traditions), lactation, and menopause.
• Adaptogen (Rasayana): Classified as one of the premier Rasayana (rejuvenative) herbs in Ayurveda, used for longevity, vitality, and stress resilience.
• Digestive (Amlapitta): Traditionally used for acid gastritis, peptic ulcers, and general digestive complaints. Preclinical studies support antiulcer activity through enhancement of mucosal defensive factors.
• Nutritive tonic: Used to build Rasa Dhatu (nutritive tissue/plasma) and Meda Dhatu (adipose tissue). Traditional preparations include Shatavari Ghrita (clarified butter preparation) and Shatavari Kalpa (sweetened granules with milk).
• Immunomodulator (Ojas-promoting): Traditional concept of building Ojas (vital essence/immunity), supported by preclinical evidence of immunostimulatory activity.

Mechanism of Action

Steroidal Saponin Estrogenic Activity

Shatavarins I-IV are steroidal saponins with sarsasapogenin as the aglycone backbone. Shatavarin I is the major glycoside, with glucose and rhamnose moieties attached to sarsasapogenin. These compounds exhibit selective estrogen receptor modulator (SERM)-like behavior, exerting estrogenic effects in some tissues while acting as antagonists in others. This phytoestrogenic activity is considered the primary mechanism underlying shatavari’s effects on female reproductive health. The steroidal saponin structure enables interaction with both ER-alpha and ER-beta, though binding affinity is substantially lower than endogenous estradiol.

Prolactin Modulation (Galactagogue Mechanism)

The galactagogue effect is mediated through modulation of prolactin secretion from the anterior pituitary. Clinical trials demonstrate significant prolactin increases following shatavari administration. The precise mechanism is not fully elucidated but may involve:

• Dopaminergic modulation at the hypothalamic level (prolactin release is regulated by dopamine inhibition)
• Steroidal saponin interaction with estrogen receptors in lactotroph cells, stimulating prolactin gene transcription
• Potential effects on prolactin-releasing factors (TRH, VIP, oxytocin)

Antioxidant Activity

Methanolic extracts at 200 mg/kg reduce oxidative stress by decreasing lipid peroxidation and increasing antioxidant enzymes (SOD, glutathione peroxidase, glutathione, catalase) in hippocampus and striatum. The isoflavones, racemosol, and polyphenolic compounds contribute to direct radical-scavenging activity.

Adaptogenic/HPA Axis Modulation

Shatavari modulates the hypothalamic-pituitary-adrenal (HPA) axis. Preclinical studies (Pandey et al., 2013; reviewed in Heliyon, 2023) demonstrate that A. racemosus extract:

• Alleviates depression-like behavior through HPA axis modulation
• Increases BDNF levels and modulates monoaminergic and GABAergic neurotransmission
• Enhances antioxidant enzyme levels (SOD, GSH peroxidase, catalase) in brain regions
• Reduces stress-induced corticosterone elevation in animal models

Immunomodulatory Activity

In vitro-produced shatavarins stimulate immune cell proliferation and IgG secretion in a dose-dependent manner. The polysaccharide fraction activates macrophages and enhances innate immune responses, providing a pharmacological basis for the traditional concept of shatavari as an “Ojas-building” herb.

Uterine Smooth Muscle Effects

Shatavarin I, isolated from the roots, competitively blocks oxytocin-induced contractions in rat, guinea pig, and rabbit uteri (both in vitro and in vivo). This antispasmodic activity on uterine smooth muscle is pharmacologically relevant to the traditional use for dysmenorrhea and as a uterine tonic.

Anti-ulcer Activity

Shatavari enhances mucosal defensive factors in the gastric mucosa, including increased mucin secretion, cytoprotective prostaglandin production, and antioxidant defense in gastric tissue. This mechanism supports the traditional Ayurvedic use for Amlapitta (acid gastritis).

Clinical Evidence Summary

Clinical evidence for shatavari has expanded considerably in 2025, though the overall evidence base remains limited by small sample sizes and short trial durations.

Galactagogue (Lactation) RCTs

Menopausal/Perimenopausal RCTs

Evidence Limitations

• Small sample sizes: Most RCTs have n=50-90, which limits statistical power and generalizability.
• Short durations: Lactation studies are typically 3-30 days postpartum; menopausal studies are 8 weeks to 4 months.
• Heterogeneous preparations: Studies use varying extract types, doses, and standardization parameters, making cross-study comparison difficult.
• Industry sponsorship: Several recent RCTs (particularly the 2025 menopausal studies) are sponsored by extract manufacturers, introducing potential bias.
• Geographic limitation: Most studies are conducted in Indian populations; cross-cultural generalizability has not been established.
• No systematic reviews or meta-analyses: As of early 2026, no published systematic review with meta-analysis has been conducted exclusively on Asparagus racemosus for any single indication.
• Mixed results in LactMed assessment: The NCBI LactMed database notes that evidence is mixed, particularly when shatavari is studied as part of multi-herb formulations rather than as a standalone agent.

Safety Profile

General Assessment

Shatavari has a long history of traditional use in Ayurvedic medicine spanning over 2000 years. Clinical trials at doses up to 500 mg/day for 8 weeks and traditional use at 3-6 g/day of root powder have not revealed serious adverse events. The herb is generally well-tolerated, but formal safety data from large-scale, long-term clinical trials are lacking.

Contraindications

• Estrogen-sensitive conditions: Due to phytoestrogenic activity (SERM-like behavior), shatavari should be avoided in estrogen receptor-positive breast cancer, endometriosis, uterine fibroids, and other hormone-sensitive conditions. While estrogenic potency is much lower than endogenous estradiol, a precautionary approach is warranted.
• Known asparagus allergy: Individuals with known allergy to asparagus (Asparagaceae family) should avoid shatavari. Allergic reactions including skin rash, respiratory symptoms, and anaphylaxis (rare) have been reported.
• Kidney disorders: Shatavari has diuretic properties that may affect sodium reabsorption and fluid balance. Use caution in individuals with renal impairment.

Drug Interactions

Side Effects (at Recommended Doses)

• Common: Generally very well-tolerated. Mild gastrointestinal symptoms (bloating, loose stools) reported occasionally, likely attributable to the high mucilage and fiber content.
• Uncommon: Diarrhea, headache, nausea.
• Rare: Allergic reactions (skin rash, urticaria, respiratory symptoms) in asparagus-sensitive individuals.
• No hepatotoxicity signal has been reported in clinical trials or post-market surveillance.

Pregnancy and Lactation

• Pregnancy: Category C — Use with caution. Ayurvedic practice considers shatavari safe during pregnancy and prescribes it as a nutritive tonic in the second and third trimesters. However, Goel et al. (2006) found that methanolic extract at 100 mg/kg/day for 60 days showed teratological effects in rats, including increased fetal resorption, gross malformations, intrauterine growth retardation, and smaller placental size. Until clearer dose-safety data exist in pregnant women, avoiding shatavari in the first trimester (during organogenesis) is prudent. This represents a notable disagreement between Ayurvedic practice and preclinical toxicology.
• Lactation: Considered safe by Ayurvedic practitioners and specifically studied as a galactagogue. Clinical trials (up to 300 mg/day for 72 hours postpartum) have not reported adverse effects in mothers or infants. Not listed as GRAS by the US FDA; long-term lactation safety data are limited.

Toxicology

• Acute toxicity: The oral LD50 in mice is greater than 2000 mg/kg/day. For intraperitoneal administration, the aqueous extract LD50 is 505 mg/kg. A single limit dose of 5000 mg/kg body weight did not cause mortality or abnormalities in mice.
• Subchronic toxicity: Subacute toxicity studies in Swiss albino mice have not revealed significant organ damage at therapeutic doses.
• Genotoxicity: No mutagenicity or genotoxicity has been reported in standard assays.
• Teratogenicity: Methanolic root extract at 100 mg/kg/day demonstrated teratogenic effects in rats (Goel et al., 2006). This contrasts with long Ayurvedic tradition and warrants further investigation of dose-response relationships and extract specificity.

Clinical Dosage

Traditional Ayurvedic Dosage

Standardized Extract Dosage (Clinical Trial Doses)

Administration Notes

• Shatavari is typically taken with warm milk in the Ayurvedic tradition, as milk is considered an Anupana (vehicle) that enhances the herb’s nourishing and cooling properties.
• Onset of clinical effects for lactation may be observed within 72 hours based on recent RCT data.
• For menopausal and hormonal indications, clinical effects typically require 4-8 weeks of consistent use based on trial data showing progressive improvement over 8-16 weeks.
• Traditional Ayurvedic dosing (3-6 g/day root powder) is substantially higher than standardized extract doses (50-500 mg), reflecting the concentration achieved through extraction.
• Duration: Clinical trials have used 72 hours to 4 months. Traditional use recommends courses of 1-3 months, which may be repeated.

Sources

• Alok S, Jain SK, Verma A, Kumar M, Mahor A, Sabharwal M. Plant profile, phytochemistry and pharmacology of Asparagus racemosus (Shatavari): A review. Asian Pac J Trop Dis. 2013;3(3):242-251
• Sharma S, Ramji S, Kumari S, Bapna JS. Randomized controlled trial of Asparagus racemosus (Shatavari) as a lactogogue in lactational inadequacy. Indian Pediatr. 1996;33(8):675-677
• Gupta M, Sharma B. A double-blind randomized clinical trial for evaluation of galactogogue activity of Asparagus racemosus Willd. Iranian J Pharm Res. 2011;13(1):167-172
• Tikare S, Gaikwad S, Kamath A, Kulkarni U. Postpartum use of Shavari Bar improves breast milk output: a double-blind, prospective, randomized, controlled clinical study. J Hum Lact. 2022;38(3):537-544
• Patel K, et al. Shatavari (Asparagus racemosus Willd) root extract for postpartum lactation: a randomised, double-blind, placebo-controlled study. J Obstet Gynaecol. 2025 (published online)
• Patel R, et al. A standardized Asparagus racemosus root extract improves hormonal balance and menstrual health and reduces vasomotor symptoms in perimenopausal women: a randomized, double-blind, placebo-controlled study. J Am Nutr Assoc. 2025;44(8)
• Efficacy and safety of Shatavari root extract (Asparagus racemosus) for menopausal symptoms: a randomized, double-blind, three-arm, placebo-controlled study. Front Reprod Health. 2025;7:1654503
• Efficacy and safety of Shatavari (Asparagus racemosus) root extract for perimenopause: randomized, double-blind, placebo-controlled study. Int J Women’s Health. 2025;17
• Pandey AK, Gupta A, Srivastava S, Mishra R, et al. Asparagus racemosus modulates the hypothalamic-pituitary-adrenal axis and brain monoaminergic systems in rats. Nutr Neurosci. 2013;16(6):255-261
• Adaptogenic property of Asparagus racemosus: future trends and prospects. Heliyon. 2023;9(4):e14932
• Goel RK, Paiwa AS, Ramnathan SK, Rao CV. Teratogenicity of Asparagus racemosus Willd. root, a herbal medicine. Indian J Exp Biol. 2006;44(7):570-573
• Bhatnagar M, Sisodia SS, Bhatnagar R. Antiulcer and antioxidant activity of Asparagus racemosus Willd and Withania somnifera Dunal in rats. Ann N Y Acad Sci. 2005;1056:261-278
• Negi JS, Singh P, Joshi GP, Rawat MS, Bisht VK. Chemical constituents of Asparagus. Pharmacogn Rev. 2010;4(8):215-220
• Hayes PY, Jahidin AH, Lehmann R, Penman K, Prager RH, De Voss JJ. Steroidal saponins from the roots of Asparagus racemosus. Phytochemistry. 2008;69(3):796-804
• Kurmi R, et al. Modulation of various pharmacological pathways by asparagus saponins: special emphasis on shatavarin-IV. Chem Biodivers. 2026;23(1):e202502360
• Wild Asparagus. Drugs and Lactation Database (LactMed). National Library of Medicine (US). Updated 2024
• Mortel M, Mehta SD. Systematic review of the efficacy of herbal galactogogues. J Hum Lact. 2013;29(2):154-162
• Ayurvedic Pharmacopoeia of India. Part I. Government of India, Ministry of Health and Family Welfare
• Asparagus racemosus monograph. Indian Pharmacopoeia Commission

Connections

• Compare with Vitex Chasteberry: Vitex has stronger European regulatory backing and acts through dopaminergic/prolactin-lowering mechanisms, while shatavari acts through phytoestrogenic and prolactin-enhancing mechanisms — mechanistically complementary rather than interchangeable
• Compare with Black Cohosh for menopausal symptoms: Black Cohosh has substantially more clinical evidence and formal European monographs; shatavari’s menopausal evidence is emerging but limited
• Compare with Red Clover as a phytoestrogen source: both contain isoflavones with SERM-like activity, but Red Clover’s isoflavone profile is better characterized
• Compare with Dong Quai as a traditional women’s health tonic from a non-European tradition: both have deep traditional roots but limited Western validation; shatavari may now have a slightly stronger evidence base due to recent RCTs
• Compare with Raspberry Leaf for pregnancy and postpartum use: raspberry leaf serves as a uterine tonic in Western herbalism, while shatavari plays a parallel role in Ayurveda with broader adaptogenic scope
• Shatavari’s adaptogenic mechanism shares features with Ashwagandha — both are premier Rasayana herbs, but shatavari is cooling (Shita Virya) while ashwagandha is warming (Ushna Virya), positioning them as complementary
• The galactagogue (prolactin-enhancing) mechanism contrasts directly with Vitex chasteberry’s prolactin-lowering effect — these herbs should not be combined without practitioner guidance